Kinetic interaction between theophylline and a newly developed anti-allergic drug, pemirolast potassium

T. Hasegawa, K. Takagi, M. Nadai, Y. Ogura, Toshitaka Nabeshima

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The effect of a newly developed anti-allergic drug, pemirolast potassium (TBX), on the pharmacokinetics and metabolism of theophylline was investigated under steady-state conditions in seven healthy male volunteers. A sustained-release theophylline formulation (100 mg twice daily at 12 h intervals) was given as monotherapy and coadministered with TBX (10 mg twice daily at 12 h). Plasma concentration-time curves and the urinary excretion of theophylline and its major metabolites after administration of theophylline alone and after coadministration with TBX were compared. No significant adverse effects from this study were observed. There were no significant differences in the total body clearance, renal clearance and maximum concentration of theophylline between the two treatments, although coadministration of TBX significantly delayed the time to reach maximum concentration of theophylline. In the case of urinary excretion, no significant changes in the fraction of urinary excretion of theophylline and its metabolites were observed. These results indicate that TBX has little or no effect on the pharmacokinetics and metabolism of theophylline and suggest that TBX is safe for asthma patients receiving theophylline therapy for treatment of chronic obstructive airway diseases.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
JournalEuropean Journal of Clinical Pharmacology
Volume46
Issue number1
DOIs
Publication statusPublished - 01-02-1994
Externally publishedYes

Fingerprint

pemirolast
Anti-Allergic Agents
Theophylline
Potassium
Pharmaceutical Preparations
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{ad76aa1604c2446f9fd55aef7787b0f8,
title = "Kinetic interaction between theophylline and a newly developed anti-allergic drug, pemirolast potassium",
abstract = "The effect of a newly developed anti-allergic drug, pemirolast potassium (TBX), on the pharmacokinetics and metabolism of theophylline was investigated under steady-state conditions in seven healthy male volunteers. A sustained-release theophylline formulation (100 mg twice daily at 12 h intervals) was given as monotherapy and coadministered with TBX (10 mg twice daily at 12 h). Plasma concentration-time curves and the urinary excretion of theophylline and its major metabolites after administration of theophylline alone and after coadministration with TBX were compared. No significant adverse effects from this study were observed. There were no significant differences in the total body clearance, renal clearance and maximum concentration of theophylline between the two treatments, although coadministration of TBX significantly delayed the time to reach maximum concentration of theophylline. In the case of urinary excretion, no significant changes in the fraction of urinary excretion of theophylline and its metabolites were observed. These results indicate that TBX has little or no effect on the pharmacokinetics and metabolism of theophylline and suggest that TBX is safe for asthma patients receiving theophylline therapy for treatment of chronic obstructive airway diseases.",
author = "T. Hasegawa and K. Takagi and M. Nadai and Y. Ogura and Toshitaka Nabeshima",
year = "1994",
month = "2",
day = "1",
doi = "10.1007/BF00195916",
language = "English",
volume = "46",
pages = "55--58",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "1",

}

Kinetic interaction between theophylline and a newly developed anti-allergic drug, pemirolast potassium. / Hasegawa, T.; Takagi, K.; Nadai, M.; Ogura, Y.; Nabeshima, Toshitaka.

In: European Journal of Clinical Pharmacology, Vol. 46, No. 1, 01.02.1994, p. 55-58.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Kinetic interaction between theophylline and a newly developed anti-allergic drug, pemirolast potassium

AU - Hasegawa, T.

AU - Takagi, K.

AU - Nadai, M.

AU - Ogura, Y.

AU - Nabeshima, Toshitaka

PY - 1994/2/1

Y1 - 1994/2/1

N2 - The effect of a newly developed anti-allergic drug, pemirolast potassium (TBX), on the pharmacokinetics and metabolism of theophylline was investigated under steady-state conditions in seven healthy male volunteers. A sustained-release theophylline formulation (100 mg twice daily at 12 h intervals) was given as monotherapy and coadministered with TBX (10 mg twice daily at 12 h). Plasma concentration-time curves and the urinary excretion of theophylline and its major metabolites after administration of theophylline alone and after coadministration with TBX were compared. No significant adverse effects from this study were observed. There were no significant differences in the total body clearance, renal clearance and maximum concentration of theophylline between the two treatments, although coadministration of TBX significantly delayed the time to reach maximum concentration of theophylline. In the case of urinary excretion, no significant changes in the fraction of urinary excretion of theophylline and its metabolites were observed. These results indicate that TBX has little or no effect on the pharmacokinetics and metabolism of theophylline and suggest that TBX is safe for asthma patients receiving theophylline therapy for treatment of chronic obstructive airway diseases.

AB - The effect of a newly developed anti-allergic drug, pemirolast potassium (TBX), on the pharmacokinetics and metabolism of theophylline was investigated under steady-state conditions in seven healthy male volunteers. A sustained-release theophylline formulation (100 mg twice daily at 12 h intervals) was given as monotherapy and coadministered with TBX (10 mg twice daily at 12 h). Plasma concentration-time curves and the urinary excretion of theophylline and its major metabolites after administration of theophylline alone and after coadministration with TBX were compared. No significant adverse effects from this study were observed. There were no significant differences in the total body clearance, renal clearance and maximum concentration of theophylline between the two treatments, although coadministration of TBX significantly delayed the time to reach maximum concentration of theophylline. In the case of urinary excretion, no significant changes in the fraction of urinary excretion of theophylline and its metabolites were observed. These results indicate that TBX has little or no effect on the pharmacokinetics and metabolism of theophylline and suggest that TBX is safe for asthma patients receiving theophylline therapy for treatment of chronic obstructive airway diseases.

UR - http://www.scopus.com/inward/record.url?scp=0028053054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028053054&partnerID=8YFLogxK

U2 - 10.1007/BF00195916

DO - 10.1007/BF00195916

M3 - Article

C2 - 8005187

AN - SCOPUS:0028053054

VL - 46

SP - 55

EP - 58

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 1

ER -